Neurodegenerative Diseases

Amylyx Pharmaceuticals hopes to launch largest PSP trial to date by the end of 2023

20-Oct-2023 By Liza Laws

The treatment of rare brain disease, progressive supranuclear palsy (PSP), that has no disease modifying therapies, has been given a glimmer of hope by Amylyx Pharmaceuticals.

'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial

16-Oct-2023 By Liza Laws

Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.

Women in Science

'Ardent wish' for cure for 'devastating' neurodegenerative diseases sparked woman's successful and fascinating career

11-Oct-2023 By Liza Laws

The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.

AstronauTx completes £48M funding for new Alzheimer's Disease therapies

09-Oct-2023 By Liza Laws

Biotech company, AstronauTx Ltd yesterday (October 9) announced the completion of a £48 million ($61 million) Series A financing.

New tool enables target discovery for new class of diseases not yet mechanically understood

26-Sep-2023 By Liza Laws

A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.

Sano Genetics receives £330k grant for platform to support at-risk patients of neurodegenerative diseases

03-Aug-2023 By Liza Laws

At-risk families of patients diagnosed with motor neurone disease (MND), better known in the US as amyotrophic lateral sclerosis (ALS) will now have access to genetic sequencing thanks to a financial award from Innovate UK.

Evotec and Bristol Myers Squibb agreement will bolster treatments for neurodenerative diseases

11-Jul-2023 By Liza Laws

A licensing agreement between Evotec SE and Bristol Myers Squibb Company (BMS) that will ‘bolster a pipeline of programmes targeting several neurodegenerative conditions’ was announced today (July 11).

Complex road ahead, despite phase 3 progress, for Annovis’ buntanetap in Parkinson’s Disease

04-Jul-2023 By Liza Laws

Drugs like Annovis Bio’s buntanetap and prasinezumab have the potential to “revolutionize the treatment of Parkinson’s Disease” says analytics company, GlobalData, an analytics company, but it is a complex road ahead.

Wearable monitor a 'game changer' in Parkson's fight, study shows

31-May-2023 By Liza Laws

Studies show a wearable monitor, described as a ‘game changer’ in the fight against Parkinson’s Disease (PD) has proven it is more than 95% accurate, PD Neurotechnology says.

Michael J Fox Foundation chooses platform to help with Parkinson's research

25-May-2023 By Liza Laws

H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.

Slowing ALS with Speech: Study leverages IBM’s AI, creates digital biomarkers

01-Dec-2022 By Maggie Lynch

First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.

ALS genetic carrier finds the “path to higher ground” in clinical research

01-Dec-2022 By Maggie Lynch

ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.

Mitochondria-focused biotech receives funding for neurodegenerative conditions

21-Nov-2022 By Ben Hargreaves

NRG Therapeutics receives an injection of capital to advance its oral medicines for Parkinson's disease and ALS.

Parkinson’s monitoring tech advances in NICE approval process

16-Aug-2022 By Jenni Spinner

The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.

Merck partners with Cerevance on Alzheimer’s research initiative

11-Aug-2022 By Jenni Spinner

The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.

Clene links ALS prospect to improved survival in open-label study

21-Jul-2022 By Nick Taylor

The biotechnology company has reported its candidate for treating amyotrophic lateral sclerosis patients has shown promising results in an early-phase study.

Machine learning can unlock potential of EEG data: Beacon Biosignals

18-May-2022 By Jenni Spinner

A leader from the neurobiomarker platform provider tells how use of ML and other advanced analytical tools can help make better use of complex information.

AARDEX to monitor adherence in patients with PTSD, neurodegenerative diseases

17-Mar-2022 By Nick Taylor

The medication adherence specialist is joining IT4Anxiety, a project focused on dealing with anxiety in patients with mental disorders, via technology.

rare disease day 2022

Genomenon forges rare-disease partnership with advocacy group

24-Feb-2022 By Jenni Spinner

The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.

Gain Therapeutics presents hopeful data for Parkinson’s, Gaucher treatment

29-Nov-2021 By Jenni Spinner

The biotech firm has presented data from a study that could offer hope to patients with Parkinson’s, Gaucher, Alzheimer’s and other neurodegenerative conditions.

Biohaven wraps patient enrollment for ALS clinical trial arm

15-Nov-2021 By Jenni Spinner

The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.

Global Genes kicks off rare-disease patient engagement effort

13-Sep-2021 By Jenni Spinner

The advocacy organization's PIE4CNS initiative is aimed at targeting and reducing gaps in diagnosis, research, and trials for rare neurological conditions.

Treg cell therapy showing promise in ALS trials: Coya Therapeutics

02-Aug-2021 By Jenni Spinner

According to the neurodegenerative-disease-focused biotechnology firm, their research could bring hope to patients with amyotrophic lateral sclerosis.

New EU pharma strategy looks to future-proof healthcare sector, stimulate innovation and boost access to biosimilars and generics

25-Nov-2020 By Jane Byrne

The new EU Pharmaceutical Strategy, adopted today by the European Commission, is designed to improve and accelerate patients’ access to safe and affordable medicines and address unmet medical needs in the areas of antimicrobial resistance, cancer, and...